Sector News

Allergan CEO says company is urgently looking at all options to boost share price

May 8, 2019
Life sciences

Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker’s falling share price, but a lack of specifics failed to boost investor sentiment.

Allergan shares fell more than 4 percent despite reporting better-than-expected first-quarter profit and raising its 2019 sales and earnings forecasts, more than twice the drop in the broader markets. They are trading nearly 60 percent below their 2015 high of about $340.

“We leave the first-quarter call with even less confidence that value in Allergan will be unlocked over the near term; catalysts are few, as are reasons to expect shares to move higher,” said RBC Capital Markets analyst Randall Stanicky.

Allergan shareholders last week voted down a non-binding proposal by activist investors that sought an immediate split of the CEO and chairman roles, but it was hardly a resounding victory for Saunders. Nearly 40 percent of shareholders backed the proposal.

Saunders said the board had talked to more than 50 shareholders recently and heard a common theme of frustration with the company’s falling stock price.

“I assure you that the board, management team and I recognize the urgency, and we will take decisive action to drive value-enhancing opportunities,” Saunders promised.

However, he did not outline any steps the board was considering, saying “everything is on the table.”

Excluding items, the company earned $3.79 per share, topping analysts’ average estimates by 24 cents, according to Refinitiv IBES data.

The company now expects 2019 adjusted profit to be greater than $16.55 per share, up from its prior expectation of greater than or equal to $16.36.

“The guidance they put out for full-year basically includes the beat in first quarter and doesn’t carry anything beyond that,” said Kevin Kedra, an analyst with Gabelli & Co, which owns Allergan’s shares.

Earnings were helped by a delay in generic competition for dry-eye drug Restasis. The company expects generic competition for Restasis later this month.

Botox sales, including cosmetic and prescription uses, rose 6.3 percent to $868.4 million, while Restasis sales fell 11.7 percent to $242 million, primarily due to lower net pricing.

U.S. sales of CoolSculpting, which removes fat non-surgically fell 27.8 percent to $62.9 million.

Revenue fell 2 percent to $3.59 billion in the quarter.

Allergan forecast 2019 sales between $15.13 billion and $15.43 billion, compared with its prior range of $15.00 billion to $15.30 billion.

By Manojna Maddipatla and Manas Mishra

Source: Reuters

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach